Announcing the Third Annual Science in the City International Symposium in Paris

#70 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians attending this symposium can access updated evidence on cannabinoid safety and efficacy, which directly improves their ability to counsel patients on therapeutic applications versus risks. The focus on clinical integration provides practical frameworks for incorporating cannabis medicines into treatment protocols when appropriate for conditions like chronic pain or epilepsy. Physician education at this level addresses the current knowledge gap many clinicians face, enabling more informed prescribing decisions and better patient outcomes in jurisdictions where cannabis is therapeutically available.
The Third Annual Science in the City International Symposium in Paris will bring together leading researchers, clinicians, and pharmaceutical experts to advance cannabinoid therapeutics and clinical integration of cannabis-based medicines. This convening addresses a critical gap in physician education, as many clinicians lack formal training in cannabis pharmacology, drug interactions, and evidence-based patient selection despite growing clinical applications. The symposium’s focus on clinical integration suggests emerging consensus on standardizing cannabinoid therapeutics within conventional medical practice, which could help legitimize cannabis as a therapeutic option while establishing quality and safety standards. For practicing physicians, participation in or awareness of such international scientific forums provides access to cutting-edge evidence and best practices in cannabinoid dosing, monitoring, and patient counseling. Clinicians seeking to responsibly incorporate cannabis into their practice should consider leveraging such educational symposia to develop competency in this rapidly evolving field.
“These symposium gatherings serve an important function in our field, bringing together the peer-reviewed literature and clinical experience we need to advance cannabinoid medicine responsibly, though I’d note that our evidence base remains uneven across different conditions, so the real work happens after the conference when we critically appraise what we heard against what the human trials actually show.”
🧠 While international symposia on cannabinoid therapeutics provide valuable forums for disseminating emerging research and fostering clinical dialogue, healthcare providers should recognize that attendance at such events, though intellectually stimulating, does not itself resolve the fundamental evidence gaps that currently limit cannabis-based treatment integration into mainstream practice. The heterogeneity of cannabis products, variable cannabinoid profiles, and limited high-quality clinical trials mean that enthusiasm at scientific conferences may outpace the actual evidence base available to individual practitioners making patient care decisions. Providers attending such meetings should maintain a critical stance toward claims about cannabinoid efficacy, carefully distinguishing between preliminary in vitro or animal data, small observational studies, and robust controlled trials that would support clinical recommendations. Practically speaking, clinicians can use these professional development opportunities to stay informed about the evolving regulatory and research landscape while tempering expectations about near-term clinical applications, and should continue to base cannabis-related counsel
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
